Tandem Diabetes Care (TNDM) News Today

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) shares traded lower today amid a mix of regulatory approvals, insider activity, analyst moves and several securities‐fraud probes.

• Positive Sentiment: FDA grants clearance for SteadiSet insulin delivery algorithm, expanding the company’s product portfolio. FDA clearance for SteadiSet
• Positive Sentiment: Shares gapped up following insider buying activity, signaling executives’ confidence in the business. Insider buying activity
• Positive Sentiment: Canaccord Genuity maintains its Buy rating, highlighting strategic growth potential and market expansion. Canaccord Genuity Buy rating
• Neutral Sentiment: Analysts issue a consensus Hold rating, reflecting mixed expectations for near-term performance. Consensus Hold rating
• Neutral Sentiment: Five insightful questions from the Q2 earnings call focus on product rollout and reimbursement dynamics, without changing guidance. Q2 earnings call questions
• Negative Sentiment: Glancy Prongay & Murray LLP launches a securities-fraud investigation, urging investors who lost money to contact the firm over alleged misrepresentations. Glancy Prongay & Murray investigation
• Negative Sentiment: The Law Offices of Howard G. Smith commences another probe into potential federal securities-law violations. Howard G. Smith investigation
• Negative Sentiment: The Law Offices of Frank R. Cruz adds a third investigation, citing disclosures around an October device malfunction. Frank R. Cruz investigation
• Negative Sentiment: Piper Sandler downgrades shares to a Hold rating, challenging recent trading momentum. Piper Sandler Hold rating
• Negative Sentiment: Lake Street Capital cuts its rating to Hold, citing valuation concerns. Lake Street Capital rating cut
• Negative Sentiment: Leerink Partnrs lowers its Q3 EPS forecast to ($0.41) from ($0.32), signaling potential margin pressures ahead.